Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
iclight,
Here are the enrollment numbers of the phase 3 CheckMate 498 study:
Patients enrolled (N = 3034)
Patients not randomized (n = 2474)
• No longer met inclusion criteria (n = 1250)a
• Administrative reason by sponsor (n = 766)a
• Withdrew consent (n = 238)
• Other (n = 198)
• Adverse event (n = 11)
• Poor/noncompliance (n = 6)
• Not reported (n = 3)
• Death (n = 2)
Randomized 1:1
Nivolumab plus radiotherapy (n = 280)
• Received allocated intervention (n = 278)
Temozolomide plus radiotherapy (n = 280)
• Received allocated intervention (n = 275)
Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial.
Antonio Omuro, MD, Alba A Brandes, MD, Antoine F Carpentier, MD, Ahmed Idbaih, MD, David A Reardon, MD, Timothy Cloughesy, MD, Ashley Sumrall, MD, Joachim Baehring, MD, Martin van den Bent, MD, Oliver Bähr, MD,
Giuseppe Lombardi, MD, Paul Mulholland, FRCP, Ghazaleh Tabatabai, MD, Ulrik Lassen, MD, Juan Manuel Sepulveda, MD, Mustafa Khasraw, MD, Elodie Vauleon, MD, Yoshihiro Muragaki, MD, Anna Maria Di Giacomo, MD, Nicholas Butowski, MD, Patrick Roth, MD, Xiaozhong Qian, PhD, Alex Z Fu, PhD, Yanfang Liu, MD, Von Potter, MD, Alexandros-Georgios Chalamandaris, PhD, Kay Tatsuoka, PhD, Michael Lim, MD, Michael Weller, MD
Published: April 14, 2022
https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noac099/6568419
Thanks eagle8.
Here are Roger Stupp's Disclosures:
Thanks hmuney.
Great summary The Danish Dude. Thanks.
Thanks ATLnsider.
If you go to the NHS webpage National tariff workbook Apr22-Annex-A - https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fwww.england.nhs.uk%2Fwp-content%2Fuploads%2F2020%2F11%2F22-23NT_Annex-A-National-tariff-workbook_Apr22.xlsx&wdOrigin=BROWSELINK , you will find a list of
Advanced Therapy Medicinal Products (ATMPs) with these remarks:
Thank you red57dryad.
Thanks pgsd,
Here's the transcription: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167653739
Interesting read about patient Fay who was eligible for the DCVax-L trial.
Emerging Tissue Economies: Personalized Immunotherapies and Therapeutic Value in Cancer.
Henry Llewellyn
Division of Psychiatry, University College London, London, UK
Published online: 13 Apr 2021
Another GoFundMe page mentioning DCVax-L.
Please help save Hannah Cohen's Life.
Created 7 day ago.
This is a very special appeal to raise money for life-saving treatment for Hannah. Having recovered from a brain tumour in 2011, her condition has taken a sudden turn for the worse.
We are waiting on the results of scans but if, as seems likely, she has another brain tumour we will need to move quickly to fund the treatment she needs.
We need to raise around £250,000 to give her the opportunity to have Immunotherapy treatment. The treatment is called ADCV and is from a pioneering company called DCVax® https://brainstrust.org.uk/gbm/gbm-treatment-trials/.
It is not available on the NHS so needs to be funded privately.
Our Story
https://www.gofundme.com/f/please-help-save-hannah-cohens-life?utm_campaign=p_cp+share-sheet&utm_medium=copy_link_all&utm_source=customer
ATLnsider,
You said:
Thanks for sharing hmuney.
Good example biosectinvestor. Thanks.
To challenge effect size observed in the Phase 2b study and to explore use of an ECA as a viable comparator arm for the Phase 3 study, Medicenna recruited an eligibility matched control group for comparison against outcome of the Phase 2b study.
Subjects recruited in ECA were identified from patient registries at two major neurosurgery centers with access to GBM tumor tissue banks under IRB-approved protocols.
In order to avoid potential bias, Medicenna was blinded to the survival data throughout the project.
An expert group in regulatory statistics and real-word data (Acorn AI) was contracted to analyze the data employing propensity score weighting methodology to adjust for baseline differences in the 2 groups (i.e. MDNA55 versus ECA)
(source: SNO 2020 Think Tank on Neuro-Oncology Clinical Trials-November 6, 2020.)
muee88,
Linda Liau will not be participating at the UCLA event of May 6, 2022.
Thanks for the additional info hyperopia.
You said:
Autolomous : presentation today.
Advent Bioservices freezer facility.
March 28, 2022
Mesobank is pleased to be partnering with Advent Bioservices Ltd, Cambridge for longer term storage of Mesobank samples. Going forward, Mesobank will use Advent’s new freezer store at their Sawston facility for off-site storage.
https://www.mesobank.com/news/advent-bioservices-freezer-facility/
About Mesobank
Mesobank is the UK’s largest collection of high-quality tissue, cells and blood samples from mesothelioma patients.
Thanks hmuney!
hoffmann6383,
Feb.9, 2022
WCM Neurosurgery Grand Rounds: Dr Linda Liau.
Dr.Bala,
Obviously, he missed the Q&A session today.
ae kusterer,
LL’s presentation (Therapy-induced resistance in glioblastoma: New Concepts) included discussion on a new trial in newly diagnosed GBM patients they will be starting in the near future.
3 arms:
Group A : ATL-DC + Pembrolizumab + PLX 3397 (N=10)
Group B : ATL-DC + PLX 3397 (N=10)
Group C : ATL-DC + Pembrolizumab (N=10)
Pembrolizumab = 400mg (6 weeks)
PLX3397 = 100mg daily oral
ATL-DC = 2 wks x 3
Thanks hope4patients!
Fleyroy,
Yes he did.
PhD student Riza made a few notes from his talk. I don't think he told the audience anything new about the trial.
The Danish Dude,
Dr Marnix Bosch was added to the Programme at the last minute.
Thanks for the info DD!
Program DAY 1
INTERNATIONAL WOMEN’S DAY: SPOTLIGHTING 5 TRAILBLAZING UCLA PROFESSORS
March 8, 2022
By Kate Green